Pacira BioSciences (PCRX) Assets Average (2011 - 2026)

Pacira BioSciences' Assets Average history runs 16 years deep, the most recent figure standing at $1.2 billion for Q1 2026.

• On a quarterly basis, Assets Average fell 21.23% year-over-year to $1.2 billion in Q1 2026; TTM through Mar 2026 was $1.2 billion, a 21.23% decrease from a year earlier, with the FY2025 full-year figure at $1.4 billion, down 9.89% from the prior year.
• Assets Average retreated to $1.2 billion in Q1 2026 per PCRX's latest filing, from $1.3 billion in the prior quarter.
• Across five years, Assets Average topped out at $2.0 billion in Q1 2022 and bottomed at $1.2 billion in Q1 2026.
• The 5-year median for Assets Average is $1.6 billion (2025), against an average of $1.6 billion.
• Across the five-year window, Assets Average jumped 54.83% in 2022 and fell 21.23% in 2026, its largest moves.
• Year by year, Assets Average stood at $1.7 billion in 2022, then declined by 8.98% to $1.6 billion in 2023, then retreated by 1.08% to $1.5 billion in 2024, then retreated by 16.67% to $1.3 billion in 2025, then slipped by 3.47% to $1.2 billion in 2026.
• Per Business Quant, the three latest PCRX Assets Average figures stand at $1.2 billion (Q1 2026), $1.3 billion (Q4 2025), and $1.4 billion (Q3 2025).